Our data are in line with previous studies showing that EGFR mutated tumors display an uninflamed phenotype [17] and that cetuximab treatment may lead to increased T-cell infiltration in head and neck cancers [28, 29]. This evidence concerns the gene EGFR and head and neck cancer.